OA: MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients

 The term “theranostics” was coined to define ongoing efforts in clinics to develop more specific, individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent.
                         ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
open access:
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients from the IFCT-0002 Phase 3 Trial

 Interpretation: DNA repair protein expression assessment identified three different groups of risk of death in early-stage lung cancer patients, according to their tumor MSH2 and BRCA1 expression levels. These results deserve prospective evaluation of MSH2/BRCA1 theranostic value in lung cancer patients treated with combinations of DNA-damaging chemotherapy and drugs targeting DNA repair, such as Poly(ADP-ribose) polymerase (PARP) inhibitors.

  In response to the lack of consensus in the literature regarding the value of these enzymes’ expression in tumors as predictive biomarkers in NSCLC [24], the IFCT 0002 Phase 3 randomized trial, with its large patient sample (528 patients enrolled between 2001 and 2005) and the homogeneity of their treatments, constituted further opportunity to assess whether or not XRCC5, MSH2, BRCA1, and O6MGMT represent reliable biomarkers in Stage I and II NSCLC patients, treated with taxane- or anti-metabolite-based perioperative chemotherapy.